Our results confirmed that LINC01468 increases CUL4A-mediated degradation of SHIP2, by which SHIP2 negatively regulates PI3K/Akt, thereby promoting lipogenesis and HCC progression; thus, SHIP2 functions as a tumor suppressor in NAFLD-HCC. The gene discussed is INPPL1; the disease is metabolic dysfunction-associated steatotic liver disease.